<unk>  is approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown-status tumors. This is its only approved use in the United States. It shows equivalent effectiveness to tamoxifen for this indication.<unk>  has been found to be effective in the treatment of breast pain and may be a more effective medication than tamoxifen for this indication. It also has superior effects on bone mineral density and lipid profile, including levels of cholesterol and triglycerides, compared to tamoxifen.<unk>  has been reported to significantly improve symptoms of gynecomastia in men. Available forms<unk>  is provided in the form of 60 mg oral tablets.
Toremifene
Tiotixene
Daridorexant
Rauwolscine
Tasimelteon
Acolbifene
Mitapivat
Seltorexant